ORAMED PHARMACEUTICALS INC. (ORMP): Submission of Matters to a Vote of Security Holders
ORAMED PHARMACEUTICALS INC. (ORMP) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 15, 2026, the Company held its 2026 Annual Meeting of Stockholders. The final voting results at the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) are set forth below. Proposal No. 1 - Re-ele
How this was made
The 30-second read
Why it matters
The filing confirms routine governance actions with no material operational or financial changes.
Market read
A standard corporate‑governance disclosure; limited relevance for traders.
What to watch
Potential future compensation alignment changes from the new say‑on‑pay frequency.
Background
ORMP held its 2026 Annual Meeting on Sep 15, 2026, and filed the results via an SEC Form 8‑K two days later.
Ticker impact
SEC Form 8‑K discloses the results of ORMP's 2026 Annual Meeting, including director re‑elections and shareholder approvals of say‑on‑pay and stock‑plan amendments.
minimal; price likely unchanged
The filing reports standard voting results; no material change to capital structure or strategy.
Market effects
none; governance update does not affect the broader pharmaceutical sector.
none; filing pertains only to ORMP shareholders.
none
Counterpoint
Investors could view the expanded stock‑incentive plan as a slight dilution risk, but the impact is negligible.
Key entities
- companyORAMED PHARMACEUTICALS INC.
Subject of the filing; a pharmaceutical company listed on US exchanges.
